Cancer no more

ARETEAI platform combines proprietary database with novel AI algorithms revealing the secrets of tumor biology.

Find out more

We have discovered that the unexplored part of tumor genomes hides huge amounts of information.

Through the use of whole genome sequencing (WGS) and other omics data, we redefine how to transform data into understanding.

More data = better understanding

We have discovered that the unexplored part of tumor genomes hides huge amounts of information.

Through the use of whole genome sequencing (WGS) and other omics data, we redefine how to transform data into understanding.

More data = better understanding

Genomic features

We use biological expertise and proprietary AI machinery to explore tumor biology and reveal genomic features. Over 90,000 custom genomic features are used as an input into the AI machinery, built by the combined expertise of biologists and data scientists.

Genomic features are numerical representations of molecular tumor characteristics - the key to understand oncogenesis.

Patterns

ARETEAI analyzes millions of genomic patterns by identifying genomic features correlated with DNA damage response activity. These patterns explain pathways malfunctioning resulting in genomic instability. 

Pathway Deconvolution

By traversing the landscape of all DNA damage response pathway interactions, ARETEAI builds a pathway activity profile for each tumor. ARETEAI uses these profiles to identify pathway-dependent tumors. Inhibition of the pathway that the tumor is addicted to, results in tumor death.

Drug target identification

By understanding pathway interactions, we have created an approach to identify new drug targets through analysis of genes that are rarely inactivated in real tumors, but are always preserved in the specific genomic context of a tumor.

ARETEAI delivers ranking of drug target candidates by identifying genes synthetically lethal to given genomic context of the real tumor.

Cohort selection

For a given drug target candidate, ARETEAI pinpoints predictive biomarkers of response. ARETEAI is a high-throughput platform for the simultaneous discovery of drug targets and predictive biomarkers.

Drug discovery

ARETEAI led us to identify MNM177, as a first-in-class drug target, aiming at the replication stress-high tumors.

Our new drug targets are validated via cell-based and in-vivo models. Selected candidates are in lead optimization stage.

We discovered
MNM177

Ineffective treatment no more

To fulfill our mission “the right therapy for every cancer patient” we have developed a set of specialized assets.

Our assets